Nektar Therapeutics (NKTR) Misses Q2 EPS by 2c

Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.39), $0.02 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $34.6 million versus the consensus estimate of $34.23 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
• NVE Corporation names new CEO and expands board to seven members